Cargando…
Fibrostenotic strictures in Crohn’s disease
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn’s disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still ev...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Association for the Study of Intestinal Diseases
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609387/ https://www.ncbi.nlm.nih.gov/pubmed/32259917 http://dx.doi.org/10.5217/ir.2019.09148 |